[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ligand Pharm (LGND)

Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,508,870
  • Shares Outstanding, K 20,041
  • Annual Sales, $ 268,090 K
  • Annual Income, $ 124,450 K
  • EBIT $ 127 M
  • EBITDA $ 157 M
  • 60-Month Beta 1.17
  • Price/Sales 19.67
  • Price/Cash Flow 35.01
  • Price/Book 5.52

Options Overview Details

View History
  • Implied Volatility 46.75% (+9.31%)
  • Historical Volatility 37.80%
  • IV Percentile 82%
  • IV Rank 40.23%
  • IV High 73.14% on 04/13/26
  • IV Low 28.98% on 08/08/25
  • Expected Move (DTE 25) 21.85 (8.58%)
  • Put/Call Vol Ratio 4.60
  • Today's Volume 235
  • Volume Avg (30-Day) 45
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 754
  • Open Int (30-Day) 897
  • Expected Range 232.94 to 276.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.21
  • Number of Estimates 4
  • High Estimate $1.63
  • Low Estimate $1.06
  • Prior Year $0.24
  • Growth Rate Est. (year over year) +404.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
222.76 +15.09%
on 06/01/26
276.20 -7.18%
on 06/18/26
+27.04 (+11.79%)
since 05/22/26
3-Month
188.67 +35.88%
on 03/30/26
276.20 -7.18%
on 06/18/26
+51.56 (+25.17%)
since 03/20/26
52-Week
110.00 +133.06%
on 06/23/25
276.20 -7.18%
on 06/18/26
+142.30 (+124.75%)
since 06/20/25

Most Recent Stories

More News
Stocks Erase Early Gains as Alphabet and Software Companies Fall

The S&P 500 Index ($SPX ) (SPY ) today is down -0.40%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.30%. September E-mini S&P futures...

MSTR : 110.45 (-1.85%)
GOOGL : 346.11 (-5.96%)
SNDK : 2,299.15 (+5.24%)
COIN : 165.30 (+1.25%)
STX : 1,073.07 (+0.27%)
AMD : 544.06 (+1.24%)
DFTX : 37.38 (+52.70%)
^BTCUSD : 64,683.99 (+2.39%)
SPY : 744.92 (-0.24%)
NOC : 507.35 (-2.71%)
FRVO : 36.97 (+5.36%)
ADSK : 186.22 (-3.92%)
Stocks Supported by Strength in Chipmakers and AI-Infrastructure Stocks

The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.54%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.50%. September E-mini S&P futures...

MSTR : 110.45 (-1.85%)
AMAT : 626.28 (+1.49%)
GOOGL : 346.11 (-5.96%)
SNDK : 2,299.15 (+5.24%)
GLXY : 33.93 (-0.79%)
$IUXX : 30,239.16 (-0.55%)
COIN : 165.30 (+1.25%)
ZNU26 : 109-070 (-0.10%)
LGND : 255.86 (-6.92%)
APGE : 132.64 (+46.76%)
ESU26 : 7,542.75 (-0.01%)
STX : 1,073.07 (+0.27%)
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031

Opportunistic capital raise with proceeds used to enhance financial flexibility  A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to...

LGND : 255.86 (-6.92%)
Ligand Announces 2026 Investor Day in New York City

JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at...

LGND : 255.86 (-6.92%)
Ligand to Participate in June Investor Conferences

JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor...

LGND : 255.86 (-6.92%)
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking...

LGND : 255.86 (-6.92%)
MDT : 79.46 (+0.15%)
OBIO : 3.96 (-0.75%)
Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key...

LGND : 255.86 (-6.92%)
Ligand: Q1 Earnings Snapshot

Ligand: Q1 Earnings Snapshot

LGND : 255.86 (-6.92%)
Ligand Reports First Quarter 2026 Financial Results

First quarter performance driven by strong year-over-year royalty revenue growth of  56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution...

LGND : 255.86 (-6.92%)
Can Ligand Pharmaceuticals Justify Its Valuation When the Royalty Growth Finally Slows?

Barchart Research What to Expect from LGND Earnings LGND Generated May 6, 2026 Current Price $231.11 EPS Estimate $$0.98 Consensus Rating Strong Buy Average Move 4.52% Can Ligand Pharmaceuticals Justify...

LGND : 255.86 (-6.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 289.09
2nd Resistance Point 282.64
1st Resistance Point 278.76
Last Price 255.86
1st Support Level 268.44
2nd Support Level 261.99
3rd Support Level 258.11

See More

52-Week High 276.20
Last Price 255.86
Fibonacci 61.8% 212.71
Fibonacci 50% 193.10
Fibonacci 38.2% 173.49
52-Week Low 110.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.